Placeholder

Leuprolide

CAS No:
53714-56-0 Category:
  • #LGM Pharma is a Leuprolide CAS# 53714-56-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 53714-56-0
  • AHFC code: 10:00.0
  • Synonyms: Leuprorelin
  • ATC Code: L02AE02
  • Chemical Formula: C59H84N16O12
  • Molecular Weight: 1209.3983
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00007 (BIOD00009, BTD00009)
  • SMILES:
  • InChl:
  • PubChem:
  • IUPAC:

Additional Details

Indication:
For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics:
Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.
Mode of Action:
Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
Metabolism:
Primarily degraded by peptidase and not by cytochrome P450 enzymes.
Toxicity:
In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.
General Reference:
Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. Pubmed Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. Pubmed Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimerês disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. Pubmed Sequence Information Link RxMed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos